Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Clinical trial NCT04052997 · COMPLETED
Trial details
- NCT number
- NCT04052997
- Sponsor
- ADC Therapeutics S.A.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-09-13
- Primary completion
- 2023-01-19
- Enrollment
- 117
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.